JP2024502465A5 - - Google Patents
Info
- Publication number
- JP2024502465A5 JP2024502465A5 JP2023541506A JP2023541506A JP2024502465A5 JP 2024502465 A5 JP2024502465 A5 JP 2024502465A5 JP 2023541506 A JP2023541506 A JP 2023541506A JP 2023541506 A JP2023541506 A JP 2023541506A JP 2024502465 A5 JP2024502465 A5 JP 2024502465A5
- Authority
- JP
- Japan
- Prior art keywords
- anticancer agent
- cancer
- composition according
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134896P | 2021-01-07 | 2021-01-07 | |
| US63/134,896 | 2021-01-07 | ||
| PCT/US2022/011497 WO2022150514A1 (en) | 2021-01-07 | 2022-01-06 | Combination therapy with for46 for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502465A JP2024502465A (ja) | 2024-01-19 |
| JP2024502465A5 true JP2024502465A5 (cg-RX-API-DMAC7.html) | 2025-01-15 |
Family
ID=82357538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541506A Pending JP2024502465A (ja) | 2021-01-07 | 2022-01-06 | がんに対するｆｏｒ４６との併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240058464A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4274661A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024502465A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230129446A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117062625A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022205348A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3204579A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022150514A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6730260B2 (ja) | 2014-09-12 | 2020-07-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6730260B2 (ja) * | 2014-09-12 | 2020-07-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
| MY192146A (en) * | 2015-11-10 | 2022-08-01 | Medimmune Llc | Binding molecules specific for asct2 and uses thereof |
| CA3043277A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Anti-cd46 antibodies and methods of use |
| JP7712206B2 (ja) * | 2019-01-28 | 2025-07-23 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の処置方法 |
| WO2022150517A1 (en) * | 2021-01-07 | 2022-07-14 | The Regents Of The University Of California | Modulation of cd46 cell surface expression and therapeutic use thereof |
-
2022
- 2022-01-06 US US18/260,657 patent/US20240058464A1/en active Pending
- 2022-01-06 AU AU2022205348A patent/AU2022205348A1/en active Pending
- 2022-01-06 KR KR1020237024102A patent/KR20230129446A/ko active Pending
- 2022-01-06 WO PCT/US2022/011497 patent/WO2022150514A1/en not_active Ceased
- 2022-01-06 CA CA3204579A patent/CA3204579A1/en active Pending
- 2022-01-06 CN CN202280019866.XA patent/CN117062625A/zh active Pending
- 2022-01-06 EP EP22737129.1A patent/EP4274661A4/en active Pending
- 2022-01-06 JP JP2023541506A patent/JP2024502465A/ja active Pending